"We are pleased with the FDA's decision, and we believe EUR-1073 has the potential to address key unmet medical needs of pediatric patients with ulcerative colitis," said Gearóid Faherty, chairman and chief executive officer. "The development of EUR-1073 is part of our strategy to develop a pipeline of gastroenterology products to be marketed by our own sales force, and we believe it would be complementary to EUR-1008, currently under review by the FDA as a treatment for exocrine pancreatic insufficiency, a digestive disease."
In April 2008, Eurand acquired exclusive U.S. and Canadian rights to market EUR-1073 from Chiesi Pharmaceutici SpA. Chiesi markets the drug as Clipper in several European countries.